Melucci v. Corcept Therapeutics Incorporated

CourtDistrict Court, N.D. California
DecidedOctober 7, 2019
Docket3:19-cv-01372
StatusUnknown

This text of Melucci v. Corcept Therapeutics Incorporated (Melucci v. Corcept Therapeutics Incorporated) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Melucci v. Corcept Therapeutics Incorporated, (N.D. Cal. 2019).

Opinion

8 UNITED STATES DISTRICT COURT

9 NORTHERN DISTRICT OF CALIFORNIA 10 SAN JOSE DIVISION 11

12 NICHOLAS MELUCCI, Case No. 19-CV-01372-LHK

13 Plaintiff, ORDER APPOINTING LEAD PLAINTIFF AND LEAD COUNSEL 14 v. Re: Dkt. Nos. 15, 17, 24, 29, 32, 58 15 CORCEPT THERAPEUTICS INCORPORATED, et al., 16 Defendants. 17

18 This case is a putative securities class action brought against Defendant Corcept 19 Therapeutics Incorporated (“Corcept”); its President and Chief Executive Officer, Joseph K. 20 Belanoff; and its Chief Financial Officer, Charles Robb. Plaintiffs in this action consist of 21 “persons and entities that purchased or otherwise acquired Corcept securities between August 2, 22 2017 and February 5, 2019, inclusive (the ‘Class Period’).” ECF No. 1 (“Compl.”) ¶ 1. Before 23 the Court are four outstanding Motions for Appointment as Lead Plaintiff and Approval of Lead 24 Counsel. 25 I. BACKGROUND 26 Corcept is a “pharmaceutical company that purports to develop medications to treat severe 27 metabolic, oncologic, and psychiatric disorders by modulating the effect of cortisol.” Id. ¶ 2. 1 Plaintiffs allege that, throughout the Class Period, Corcept’s “positive statements about the 2 Company’s business, operations, and prospects were materially misleading and/or lacked a 3 reasonable basis,” in light of the following: 4 (1) that the Company had improperly paid doctors to promote its drug Korlym; (2) that the Company aggressively promoted Korlym for off-label uses; (3) that the 5 Company’s sole specialty pharmacy was a related party; (4) that the Company artificially inflated its revenue and sales using illicit sales practices through a related 6 party; (5) that such practices are reasonably likely to lead to regulatory scrutiny. 7 Id. at ¶ 8. Plaintiffs claim that, as the public became aware of the truth, the revelations gradually 8 impacted the share price, culminating in “significant losses and damages.” See id. ¶¶ 3–9. 9 After the instant suit was filed and notice publicized regarding the pendency of this case, 10 the Court received five motions to appoint lead plaintiff and approval of lead counsel. The first is 11 Plaintiff Robert Baffa’s motion for appointment of Baffa as lead plaintiff and approval of Baffa’s 12 selection of counsel. ECF No. 15. The second motion was filed by Plaintiffs Ferraro Family 13 Foundation, Inc. and James L. Ferraro (collectively, the “Ferraro Group”), requesting appointment 14 of the group as lead plaintiff and approval of its selection of counsel. ECF No. 17. The third is 15 Plaintiff Bucks County Employees Retirement Fund’s (“BCERF”) motion for appointment of 16 BCERF as lead plaintiff and approval of its selection of counsel. ECF No. 24. The fourth is 17 Plaintiff Nicholas Melucci’s motion for appointment of Melucci as lead plaintiff and approval of 18 its selection of counsel. ECF No. 29. The fifth is Plaintiff Nova Scotia Health Employees 19 Pension Plan’s (“NSHEPP”) motion for appointment of NSHEPP as lead plaintiff and approval of 20 its selection of counsel. ECF No. 32. 21 Baffa withdrew his motion, ECF No. 44, as did BCERF, ECF No. 42. The Court denied a 22 stipulation by the Ferraro Group and NSHEPP proposing a co-lead plaintiff structure, ECF No. 55, 23 after which BCERF filed a response purporting to renew its motion to serve as lead plaintiff and 24 for approval of its choice of counsel.1 ECF No. 58. 25 26 1 Following the Court’s denial of the joint stipulation, the Ferraro Group and NSHEPP filed letter 27 “responses” to the denial. See ECF Nos. 56, 57. The parties are advised that the Court does not allow such filings and will not consider them in the future. 1 II. LEGAL STANDARD 2 The Private Securities Litigation Reform Act (“PSLRA”), 15 U.S.C. § 78u–4, governs the 3 selection of a lead plaintiff in private securities class actions. In the PSLRA’s own words, this 4 plaintiff is to be the “most capable of adequately representing the interests of class members.” 15 5 U.S.C. § 78u–4(a)(3)(B)(i). Under the PSLRA, a three-step process determines the lead plaintiff. 6 In re Cavanaugh, 306 F.3d 726, 729 (9th Cir. 2002). First, the first plaintiff to file an action 7 governed by the PSLRA must publicize the pendency of the action, the claims made, and the 8 purported class period “in a widely circulated national business-oriented publication or wire 9 service.” 15 U.S.C. § 78u–4(a)(3)(A)(i)(I). This notice must state that “any member of the 10 purported class may move the court to serve as lead plaintiff.” 15 U.S.C. § 78u–4(a)(3)(A)(i)(II). 11 Second, the court must select the presumptive lead plaintiff. See In re Cavanaugh, 306 12 F.3d at 729–30 (citing 15 U.S.C. § 78u–4(a)(3)(B)(iii)(I)). In order to determine the presumptive 13 lead plaintiff, “the district court must compare the financial stakes of the various plaintiffs and 14 determine which one has the most to gain from the lawsuit.” Id. at 730 (footnote omitted). Once 15 the district court identifies the plaintiff with the most to gain, the district court must determine 16 whether that plaintiff, based on the information he provides, “satisfies the requirements of Federal 17 Rule of Civil Procedure 23(a), in particular those of ‘typicality’ and ‘adequacy.’” Id. If he does, 18 that plaintiff becomes the presumptive lead plaintiff. Id. If not, the court turns to the plaintiff with 19 the next-largest financial stake and determines whether that plaintiff satisfies the requirements of 20 Rule 23. Id. The court repeats this process until it selects a presumptive lead plaintiff. Id. 21 Third, those plaintiffs not selected as the presumptive lead plaintiff may “rebut the 22 presumptive lead plaintiff's showing that it satisfies Rule 23’s typicality and adequacy 23 requirements.” Id. (citing 15 U.S.C. § 78u–4(a)(3)(B)(iii)(II)). This is done by showing that the 24 presumptive lead plaintiff either “will not fairly and adequately protect the interests of the class” 25 or “is subject to unique defenses that render such plaintiff incapable of adequately representing the 26 class.” 15 U.S.C. § 78u–4(a)(3)(B)(iii)(II)(aa)-(bb). If the court determines that the presumptive 27 lead plaintiff does not meet the typicality or adequacy requirement, then it must return to step two, 1 select a new presumptive lead plaintiff, and again allow the other plaintiffs to rebut the new 2 presumptive lead plaintiff’s showing. In re Cavanaugh, 306 F.3d at 731. The court repeats this 3 process “until all challenges have been exhausted.” Id. 4 Under the PSLRA, the lead plaintiff is given the right, subject to court approval, to select 5 counsel to represent the class. 15 U.S.C. § 78u–4(a)(3)(B)(v). “[T]he district court should not 6 reject a lead plaintiff's proposed counsel merely because it would have chosen differently.” Cohen 7 v. U.S. Dist. Court, 586 F.3d 703, 711 (9th Cir. 2009). “[I]f the lead plaintiff has made a 8 reasonable choice of counsel, the district court should generally defer to that choice.” Id. at 712. 9 III.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Staton v. Boeing Co.
327 F.3d 938 (Ninth Circuit, 2003)
Monier v. Apfel
22 F. Supp. 2d 1035 (E.D. Missouri, 1998)
In Re Olsten Corp. Securities Litig.
3 F. Supp. 2d 286 (E.D. New York, 1998)
In re Diamond Foods, Inc., Securities Litigation
281 F.R.D. 405 (N.D. California, 2012)
Schwartz v. Harp
108 F.R.D. 279 (C.D. California, 1985)

Cite This Page — Counsel Stack

Bluebook (online)
Melucci v. Corcept Therapeutics Incorporated, Counsel Stack Legal Research, https://law.counselstack.com/opinion/melucci-v-corcept-therapeutics-incorporated-cand-2019.